Introduction {#sec1}
============

The only potentially curative therapy for esophageal cancer is the esophagectomy in T1b and higher stages and endoscopic resection in the T1a stage. The treatment protocol includes neoadjuvant or adjuvant therapy consisting of systemic chemotherapy and external beam radiation in T3 and higher stages. The most serious risk of surgical treatment is presented by the development of respiratory complications (RC), with respiratory failure and adult respiratory distress syndrome (ARDS) as the leading causes of postoperative morbidity and mortality. Further important complications comprise ischemic conduit necrosis (gastric conduit in 0.5%, colonic interposition in 13%) \[[@cit0001]\] and anastomotic leakage (5--20%) with a significant risk of severe mediastinitis development, especially in the thoracic anastomosis. The identification of risk factors for RC should lead to the implementation of tailored prophylactic and therapeutic intervention. The active approach may be the bridge to a further decrease in lethal and complicated postoperative outcomes.

Aim {#sec2}
===

The aim was to evaluate the incidence and outcomes of RC following hybrid esophagectomy for esophageal malignancies. Primary endpoints were the identification of basic risk factors for RC development and their relation to morbidity and mortality.

Material and methods {#sec3}
====================

A retrospective single tertiary center analysis of the RC was applied to the cohort of esophageal cancer patients undergoing transhiatal or transthoracic esophagectomy in the period 2005--2016. The incidence of RC was assessed in relation to age (≤ versus \> 60 years), ASA score, neoadjuvant therapy, type of surgical procedure (transhiatal or transthoracic approach), the incidence of anastomotic leakage, TNM stage and Clavien-Dindo classification of postoperative complications ([Table I](#t0001){ref-type="table"}) \[[@cit0002]\]. Esophageal cancer was diagnosed by endoscopy with biopsy, endosonography, and positron emission tomography (PET)/computed tomography (CT) examination. In the case of an upper third esophageal tumor, bronchoscopy was performed to exclude tumorous airway infiltration. General internal and nutritional status and spirometry were completed preoperatively with attributed ASA classification. Since 2012, the sputum and a throat swab for microbiological examination were collected from all patients 7 days prior to surgery. In the silent lower respiratory tract infection, targeted antibiotic therapy was administered and the procedure was postponed. In the case of minimal sputum contamination values without clinical signs of lower respiratory tract infection, antibiotic prophylaxis based on microbiological culture was administered.

###### 

Clavien-Dindo classification of surgical complications

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Grade   Definition
  ------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  I       Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, or radiological interventions. Allowed therapeutic regimens include drugs such as antiemetics, antipyretics, analgesics, diuretics, electrolytes, and physiotherapy. This grade also includes wound infections opened at the bedside

  II      Requirement for pharmacological treatment with drugs other than those allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included

  IIIa    Requirement for surgical, endoscopic or radiological intervention not under general anesthesia

  IIIb    Requirement for surgical, endoscopic or radiological intervention under general\
          anesthesia

  IVa     Life-threatening complications (including CNS complications) requiring IC/ICU management. Single organ dysfunction (including dialysis)

  IVb     Life-threatening complications (including CNS complications) requiring IC/ICU management. Multiple organ dysfunction

  V       Death of the patient
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Esophagectomy was primarily performed in all patients with stages T1,2 N0 M0. Patients with higher T stages without evidence of metastatic disease were indicated for neoadjuvant therapy. This encompassed three cycles of chemotherapy (5-fluorouracil, cisplatin) and concomitant external beam radiotherapy (2 Gy per fraction to a total dose of 50 Gy). In the case of stenosis with significant dysphagia, jejunostomy was carried out prior to the neoadjuvant treatment. Subsequent restaging (PET/CT and endoscopy) together with clinical and laboratory examination evaluated the effect of neoadjuvant treatment. The eligible patients were scheduled for esophagectomy within 8--12 weeks after neoadjuvant therapy completion. The hybrid esophagectomy technique consisted of a minimally invasive approach in the resection phase (transhiatal laparoscopic or thoracoscopic) and the limited open approach for reconstruction of the digestive tract. Transhiatal minimally invasive esophagectomy was indicated in a tumor location in the distal third of the esophagus. In thoracic esophageal tumors within 30 cm of the incisors, the transthoracic approach was selected. In the transhiatal approach, the standard mediastinal lymphadenectomy was performed up to the tracheal bifurcation. In the case of thoracoscopic access, an extended thoracic lymphadenectomy was performed. The reconstruction phase consisted of the limited open gastric conduit construction with extramucosal pyloromyotomy. The manual continuous single-layer anastomosis was constructed in the deep cervical space. The postoperative care required advanced intensive postoperative care. The nutrition was provided by a combination of enteral and parenteral therapy. On postoperative day 7, a follow-up radiologic study with water-soluble contrast was performed in order to verify the reconstruction with subsequent gradual peroral food intake. The presence of RC was evaluated by the clinical examination, laboratory markers, chest radiographs, and CT findings.

The retrospective evaluation of a group of patients with esophageal cancer was approved by the local Ethical Committee.

Statistical analysis {#sec3.1}
--------------------

IBM SPSS Statistics version 22 was used to analyze the data. The χ^2^ test or Fisher's exact test was used in the case of low frequencies to determine the association between the occurrence of RC and qualitative parameters. The association between the incidence of RC and the quantitative parameters was assessed using the Kruskal-Wallis test. The normality of the data was tested using the Shapiro-Wilk test. The level of statistical significance was set at 0.05.

Results {#sec4}
=======

The surgery was provided in 215 patients, 187 (87%) men and 28 (13%) women with the age of 34--81 (median 61) years. Adenocarcinoma was found in 129 (60%) patients, squamous cell carcinoma in 81 (37.7%) and other tumor histology in 5 (2.3%) cases. The neoadjuvant therapy was indicated in 174 (80.9%) patients with the tumor stages of T 3-4, N 0-2, M 0. The stratification of the ASA classification consisted of ASA I in 7 (3.3%), ASA II in 107 (49.3%) and ASA III in 101 (47.4%) cases. The transhiatal laparoscopic approach was used in 176 (81.9%) and thoracoscopy in 39 (18.1%) patients. In distal tumors, the resection phase was performed through the transhiatal laparoscopic approach. The tumors of the thoracic esophagus required conversion from thoracoscopic resection to thoracotomy in 7 (17.9%) cases due to bulky masses with possible airway infiltration. The number of resected lymph nodes ranged from 2 to 38, with a median of 11. The estimated blood loss ranged from 100 to 3500 ml with a median of 400 ml ([Table II](#t0002){ref-type="table"}). Respiratory complications developed in 86 (40%), and severe respiratory failure or ARDS occurred in 29 (13.5%) patients. The multidisciplinary therapy (artificial pulmonary ventilation, tracheostomy, bronchoscopic therapy, antibiotics) was successful in 15 (51.7%) patients. Less severe RC including pneumonia, pleural effusion, pneumothorax and pulmonary atelectasis occurred in 57 (26.5%) patients. These complications were treated with targeted antibiotic therapy, chest drainage, and bronchoscopic flushing. Chylothorax was confirmed in 6 (2.7%) patients, the ligation of the thoracic duct was performed in 2 (0.9%) patients, while the conservative therapy was successful in other cases. Cardiac complications developed in a total of 21 (9.7%) patients and led to one death due to myocardial infarction on postoperative day 4. Necrosis of the gastric conduit and subsequent septic shock resulted in one death on postoperative day 28. A cervical anastomotic leak was found in a total of 22 (10.2%) patients. The condition required surgical revision with drainage in 7 (31.8%) and implantation of a covered biodegradable stent in 2 (9%) cases. Conservative management was applied in the other 13 (59.2%) patients. A postoperative tracheoesophageal fistula was demonstrated in 2 (9%) cases and required biodegradable esophageal stent implantation. The esophageal stenting was successful in all cases. Paralysis of the left recurrent nerve was confirmed in 19 (8.8%) patients. The overall complication-related mortality reached 7.4% (16 patients). The 30-day mortality observed in the cohort was 5.6% (RC 9, myocardial infarction 1, and necrosis of the conduit 1), and the further 90-day mortality was 1.8% (multiple organ failure). The complications were assessed according to the Clavien-Dindo classification ([Table II](#t0002){ref-type="table"}). A significant correlation of the incidence of RC with the ASA score (*p* = 0.0002) and the Clavien-Dindo classification (*p* \< 0.0001) was identified. In patients with RC, ASA classes II or III were found to be significantly more common. In patients with severe RC (respiratory failure or ARDS), Clavien-Dindo classes 4 and 5 were significantly more common as compared to less severe RC (pleural effusion, pneumothorax, pneumonia, atelectasis) or no complications ([Table III](#t0003){ref-type="table"}). The incidence of RC significantly correlated with the length of hospital stay (*p* \< 0.0001) and the postoperative fatal outcome (*p* \< 0.0001) ([Table IV](#t0004){ref-type="table"}). The implementation of active preoperative management of respiratory infections (sputum microbiology, antibiotic sensitivity, treatment of clinically silent infections, targeted prophylaxis) reduced the mortality by 2.4%.

###### 

Characteristics of the group of patients managed using minimally invasive hybrid laparoscopic and thoracoscopic esophagectomy

  Parameter              *N* (%)      MIE laparoscopic   MIE thoracoscopic
  ---------------------- ------------ ------------------ -------------------
  Gender:                                                
   Male                  187 (87)     153                34
   Female                28 (13)      23                 5
  Age \[years\]:                                         
   ≤ 60                  92 (42.7)    72                 20
   \> 60                 123 (57.3)   104                19
  Tumor type:                                            
   Adenocarcinoma        129 (60)     122                7
   Squamous cell         81 (37.7)    51                 30
   Other histology       5 (2.3)      3                  2
  Neoadjuvant therapy:                                   
   Yes                   174 (80.9)   157                27
   No                    31 (19.1)    19                 12
  ASA score                                              
   I                     7 (3.3)      6                  1
   II                    107 (49.3)   91                 16
   III                   101 (47.4)   79                 22

###### 

Statistical evaluation of respiratory complications (mild -- pneumothorax, pleural effusion, pneumonia, atelectasis; severe -- ARDS, respiratory failure) based on the considered parameters

  Parameter                         Without respiratory complications   Mild respiratory complications   Severe respiratory complications   Fisher's exact test *p*
  --------------------------------- ----------------------------------- -------------------------------- ---------------------------------- -------------------------
  Age \[years\]:                    0.276                                                                                                   
   ≤ 60                             63 (48.8%)                          25 (43.9%)                       18 (62.1%)                         
   \> 60                            66 (51.2%)                          32 (56.1%)                       11 (37.9%)                         
  Tumor type:                       0.242                                                                                                   
   Adenocarcinoma                   84 (65.1%)                          29 (50.9%)                       16 (55.2%)                         
   Squamous cell                    41 (31.8%)                          27 (47.4%)                       13 (44.8%)                         
   Other histology                  4 (3.1%)                            1 (1.8%)                         0 (0%)                             
  Neoadjuvant therapy:              0.469                                                                                                   
   Yes                              107 (82.9%)                         43 (75.4%)                       24 (82.8%)                         
   No                               22 (17.1%)                          14 (24.6%)                       5 (17.2%)                          
  ASA score:                        0.0002                                                                                                  
   I                                5 (3.9%)                            2 (3.5%)                         0 (0%)                             
   II                               72 (55.8%)                          31 (54.4%)                       4 (13.8%)                          
   III                              52 (40.3%)                          24 (42.1%)                       25 (86.2%)                         
  Procedure type:                   0.302                                                                                                   
   MIE laparoscopic                 106 (82.2%)                         49 (86.0%)                       21 (72.4%)                         
   MIE thoracoscopic                23 (17.8%)                          8 (14.0%)                        8 (27.6%)                          
  Anastomotic fistula:              0.124                                                                                                   
   Yes                              120 (93.0%)                         49 (86.0%)                       24 (82.8%)                         
   No                               9 (7.0%)                            8 (14.0%)                        5 (17.2%)                          
  TNM stage:                        0.090                                                                                                   
   Complete pathological response   22 (17.1%)                          12 (21.1%)                       4 (13.8%)                          
   I.A                              12 (9.3%)                           8 (14.0%)                        2 (6.9%)                           
   I.B                              12 (9.3%)                           12 (21.1%)                       1 (3.4%)                           
   II.A                             27 (20.9%)                          5 (8.8%)                         5 (17.2%)                          
   II.B                             15 (11.6%)                          8 (14%)                          4 (13.8%)                          
   III.A                            16 (12.4%)                          4 (7.0%)                         3 (10.3%)                          
   III.B                            10 (7.8%)                           2 (3.5%)                         5 (17.2%)                          
   III.C                            12 (9.3%)                           5 (8.8%)                         3 (10.3%)                          
  Clavien-Dindo:                    \< 0.0001                                                                                               
   1                                26 (27.7%)                          7 (13.7%)                        0 (0%)                             
   2                                47 (50.0%)                          29 (56.9%)                       0 (0%)                             
   3                                13 (13.8%)                          14 (27.8%)                       4 (13.8%)                          
   4                                6 (6.4%)                            1 (2.0%)                         11 (37.9%)                         
   5                                2 (2.1%)                            0 (0%)                           14 (48.3%)                         

###### 

Association of incidence of respiratory complications and quantitative parameters (Kruskal-Wallis test)

  Parameter                Without respiratory complications   Mild respiratory complications   Severe respiratory complications   Kruskal-Wallis *p*
  ------------------------ ----------------------------------- -------------------------------- ---------------------------------- --------------------
  Age \[years\]:           0.644                                                                                                   
   Median                  61.0                                63.0                             59.0                               
   Minimum                 34                                  44                               37                                 
   Maximum                 78                                  79                               81                                 
  Lymphadenectomy:         0.366                                                                                                   
   Median                  11.0                                10.0                             11.0                               
   Minimum                 2                                   0                                3                                  
   Maximum                 27                                  38                               21                                 
  Blood loss \[ml\]:       0.713                                                                                                   
   Median                  450                                 410                              400                                
   Minimum                 100                                 120                              140                                
   Maximum                 3000                                3500                             3500                               
  Hospital stay \[day\]:   \< 0.0001                                                                                               
   Median                  15.0                                18.0                             28.0                               
   Minimum                 9                                   11                               9                                  
   Maximum                 119                                 73                               76                                 

Discussion {#sec5}
==========

Esophagectomy is one of the most demanding procedures in gastrointestinal surgery. The procedure can be performed using the open approach, the hybrid technique (combination of a classical and minimally invasive procedure) or the totally minimally invasive method \[[@cit0003]\]. Based on the current literary evidence, most centers prefer the minimally invasive approach in the resection phase combined with the limited open approach for gastrointestinal tract reconstruction \[[@cit0004], [@cit0005]\]. The reported mortality of esophagectomy reaches 1--5.8%, with the morbidity ranging from 17.9% to 58% \[[@cit0006], [@cit0007]\] and the postoperative complication rate of 20--50% \[[@cit0008], [@cit0009]\]. Respiratory complications are the most common cause of death, ranging from 19.3% (Mariette) to 44.4% (Ott) \[[@cit0010]--[@cit0012]\]. Ott *et al.* reported 3.8% mortality in 240 patients following Ivor-Lewis esophagectomy for distal esophageal adenocarcinoma, but 50% of the deaths were caused by RC \[[@cit0006]\]. The overall mortality of the 379 cases reported by Atkins *et al.* was 5.8% \[[@cit0007]\]. Pneumonia as the dominant respiratory cause of death was reported in 54%, leading to secondary respiratory failure in 81% \[[@cit0007]\]. Siewert *et al*. published a cohort of 432 stage I--IV patients (according to the UICC classification), who underwent transthoracic or transhiatal esophageal resection. Respiratory complications (pneumonia or ARDS) developed in 22.9%. Baba et al. reported RC in 23.6% after three-space esophageal dissection \[[@cit0012]\]. The occurrence of RC is particularly increased in elderly patients, in chronic nicotine abuse, malnutrition, pulmonary dysfunction and immune deficiency \[[@cit0007], [@cit0011]\]. Further factors related to the development of RC include the operating times and estimated blood loss, FEV~1~ reduction on spirometry, neoadjuvant therapy, and the development of anastomotic leakage \[[@cit0013]--[@cit0016]\]. The incidence of RC can be influenced by the preoperative improvement of lung function and gentle anesthesia with early extubation \[[@cit0017], [@cit0018]\]. Our experience supports the possible reduction of RC following preemptive antibiotic therapy with a significant decrease in mortality. This approach requires further studies.

If there is no general or local contraindication present, we prefer the minimally invasive approach for the resection phase of the procedure, anticipating the prevention of RC. Early weaning within 24 h after surgery and general and respiratory rehabilitation are required according to the postoperative recovery recommendations.

To unify the reporting of the post-esophagectomy complications, the "Consensus on Standardization of Data Collection for Complications Associated with Esophagectomy: Esophagectomy Complications Consensus Group (ECCG)" was published in 2015 \[[@cit0019]\]. According to this consensus, RC were divided into pneumonia, pleural effusions requiring thoracic drainage, pneumothorax requiring therapy, atelectasis requiring bronchoscopic treatment, acute aspiration, tracheobronchial injury, chest drainage for more than 10 days due to air leakage, respiratory failure requiring reintubation, and ARDS \[[@cit0020]\]. In particular, respiratory failure with reintubation and ARDS contribute to the increased mortality, while the other less serious complications are reflected in the increased postoperative morbidity. One of the most serious RC is the shock lung (ARDS), which was first described by Ausbagh *et al.* in 1967 in patients with an oxygenation disorder, reduced lung compliance and bilateral pulmonary infiltrates. The syndrome is exhibited in severe acute diseases with the clinical manifestation within 12--48 h. The prognosis is serious with the reported mortality of 30--60% \[[@cit0021]\]. Zhang *et al.* demonstrated a significantly higher incidence of pneumonia in patients after chemoradiation in a study evaluating the effect of neoadjuvant chemotherapy and chemoradiation and the incidence of RC. There was no difference in the occurrence of ARDS, atelectasis, pleural effusions and respiratory failure in these two groups \[[@cit0022]\]. The literature does not describe a significant difference in the occurrence of RC in esophageal resection performed by the transthoracic or transhiatal approach \[[@cit0014]\]. Wan *et al.* did not observe a significant decrease in the incidence of RC following the thoracolaparoscopic method with cervical anastomosis compared to a control group of patients managed by classical McKeown esophagectomy \[[@cit0022]\]. We demonstrated significantly higher occurrence of RC in higher ASA scores and in Clavien-Dindo classes IV--V, underlining the negative impact of RC on mortality. We did not observe significantly higher incidence of RC in elderly patients in the age group over 60 years and in patients following neoadjuvant therapy. The reported results also show insignificant differences in the development of RC in patients managed via the minimally invasive transhiatal or thoracoscopic approach. The leak was not a cause of more frequent RC according to our statistical analysis \[[@cit0023]\]. The incidence of RC is generally considered to be a negative prognostic factor determining long-term outcomes after esophagectomy \[[@cit0024]\].

Conclusions {#sec6}
===========

It is not possible to eliminate post-esophagectomy RC in esophageal cancer patients completely. The results of our center show a higher occurrence of RC in polymorbid patients and patients with severe complications according to the Clavien-Dindo classification. As for the other parameters considered, there was no significant difference in the development of RC. The preoperative microbiological examination with subsequent targeted antibiotic prophylaxis and preemptive therapy of RC and the impact on morbidity require further studies.
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